Clinical Trial Update: A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of omalizumab (Xolair) in chronic idiopathic urticaria and chronic spontaneous urticaria patients who remaine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria
• Spontaneous Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Idiopathic Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2013-10-18